Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Romark Alinia "approvable" for adults, approval for children

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Romark Labs' Alinia (nitazoxanide) tablet formulation is deemed "approvable" for adult patients 12 years and older Nov. 22. FDA clears the oral suspension for pediatric patients ages one to 11 years on the same day. The new molecular entity is indicated for treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia. Alinia is also pending at FDA for use in AIDS patients. Romark says the product will be available in February 200

You may also be interested in...



Romark Alinia Tab. Approval Expected First Half 2004; AIDS Claim To Follow

Romark expects approval in the first half of 2004 for a tablet formulation of its antimicrobial Alinia for use in immunocompetent adults and adolescents with diarrhea associated with Giardia lamblia and Cryptosporidium parvum.

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel